Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T‐cells

Abstract

We developed a functional chimeric TCR against PSCA for treatment of PCa. The chimeric alpha-PSCA-beta2/CD3zeta-TCR might now be used for arming human cytotoxic T-cells for further studies towards a clinical treatment of PCa.